Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
phenprocoumon · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A: phenprocoumon single dose | ACTIVE_COMPARATOR | - |
| B: vemurafenib + phenprocoumon single dose | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| phenprocoumon | DRUG | 6 mg oral single dose |
| vemurafenib | DRUG | 960 mg bid orally |
Inclusion Criteria: * Adult patients, 18-70 years of age * Patients with either unresectable Stage IIIc or IV BRAFV600 mutation-positive metastatic melanoma or other malignant BRAFV600 mutation-positive tumor type and who have no acceptable standard treatment options * Eastern Cooperative Oncology ...
Phenprocoumon is a small molecule being studied in oncology. It was evaluated in a Phase 1 clinical trial for patients with malignant melanoma and neoplasms, specifically those with BRAFV600 mutation-positive metastatic malignancy.
Phenprocoumon is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company sponsored a Phase 1 clinical trial of the drug in oncology.
Phenprocoumon is in Phase 1 clinical development. It has completed one Phase 1 trial, which was an active-controlled, randomized study. The drug is investigational and not approved for any use.
Phenprocoumon was studied in clinical trial NCT01849666, titled "A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy." The trial enrolled 2 participants and was completed.
Phenprocoumon is a small molecule being studied in combination with vemurafenib in patients with BRAFV600 mutation-positive metastatic malignancy. The trial assessed how vemurafenib affects the pharmacokinetics of phenprocoumon in this patient population.
Yes, the Phase 1 clinical trial of phenprocoumon was randomized and active-controlled. It was not double-blind. The study enrolled 2 patients aged 18 years and older with malignant melanoma or neoplasms.